Introduction {#s1}
============

In December 2019, rapidly expanding pneumonia clusters of unknown aetiology were detected in the Chinese city of Wuhan, capital of Hubei province. On 9 January 2020, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was declared responsible for the outbreak of the disease, then named coronavirus disease 2019 (COVID-19) \[[@C1]--[@C3]\]. The number of COVID-19 diagnoses grew rapidly, with fast global spreading of disease: on 11 March 2020, the World Health Organization declared a pandemic state \[[@C3], [@C4]\]. By 14 April 2020, 1 844 863 confirmed cases and 117 021 deaths were registered \[[@C5]\]. SARS-CoV-2 represents the third coronavirus-mediated threat to global health of the past decades, after SARS-CoV and Middle East respiratory syndrome coronavirus \[[@C6]--[@C9]\].

SARS-CoV-2 is transmitted through respiratory droplets and enters target cells through the angiotensin-converting enzyme 2 (ACE2) receptor \[[@C10], [@C11]\]. After an incubation of 2--14 days, a symptomatic phase may manifest, with fever, short breath, coughing and possible progression to pneumonia, severe respiratory dysfunction and global deterioration. Disease assessment and monitoring is performed, together with serological testing, using plain chest computed tomography (CT) scans, showing bilateral abnormalities (ground-glass, interstitial involvement, crazy paving) in ≥75% of cases \[[@C12]\].

Severe disease is associated with conditions such as acute respiratory distress syndrome (ARDS) and with laboratory abnormalities including leukopenia, thrombocytopenia and hypercoagulative state with D-dimer elevation \[[@C2]\]. Among the factors associated with a composite end-point (CEP) (defined as intensive care unit (ICU) access, invasive ventilation and death) are comorbidities, older age and ARDS \[[@C2]\]. Similarly, the procoagulant state, particularly D-dimer elevation, has demonstrated an association with ARDS and a CEP \[[@C2]\].

The aim of this study was to analyse SARS-CoV-2 coagulation deregulatory effects, especially referring to D-dimer elevation and its correlation with thrombotic events, ARDS and a CEP.

Materials and methods {#s2}
=====================

Data sources and searches {#s2a}
-------------------------

An online database search on PubMed, Google Scholar, Scopus, Web of Science, and Cochrane was performed from 13 March 2020 to 10 April 2020. The keywords and their variants (differently combined) used for the search were "COVID-19", "2019-nCoV", "2019 novel coronavirus", "SARS-CoV-2", "D-dimer", "coagulation", "hypercoagulative state", "laboratory analysis", "ARDS", "haemostasis", "thrombosis", "pulmonary embolism", "disseminated intravascular coagulation (DIC)", "heparin" and "anti-coagulation".

Study selection {#s2b}
---------------

The inclusion criteria were as follows: COVID-19 populations, presence of laboratory test values including coagulation parameters (D-dimer specifically), and D-dimer correlation with study population characteristics. The exclusion criteria were: patients included in the study who were aged \<14 years, absence of D-dimer values, conference abstracts, commentary abstracts, letters to authors, articles written with a non-Arabic alphabet with no available translation, and case reports. Pre-published previews of accepted articles were considered as includible. References of included works were also evaluated.

The abstracts/full texts of all the studies that emerged from the search were compared to the inclusion criteria. The study search and selection process is schematised in the flow diagram shown in [figure 1](#F1){ref-type="fig"}. The selection of documents that met the inclusion criteria was independently conducted by three reviewers (S. Vidali, M.L.E. Luisi and E. Cossu).

![Flow diagram of the study search and selection process.](00260-2020.01){#F1}

Quality assessment and data extraction {#s2c}
--------------------------------------

Overall quality was evaluated using the Newcastle--Ottawa Scale (NOS) \[[@C13]\], which includes items about selection, comparability and outcome/exposure. The NOS score ranges from 0 to 9 for cohort and case--control studies; publications with a score ≥6 were considered of good quality. For cross-sectional studies the NOS score ranges from 0 to 10; a score ≥7 points was used to identify studies with good quality. The evaluation was performed by three independent reviewers (S. Pancani, D. Morosetti and G. Consales).

A data extraction scheme was designed to address the search questions of this review, consisting of the title of the article, authors, study aim, sample size, mean/median age and sex composition of samples, reference to the mean/median values measured for the D-dimer variable, eventual comparative elaboration and significance, and main findings of the study. The extracted data were compiled into a Microsoft Excel spreadsheet.

Selection bias reduction was addressed by thoughtfully designing the search protocol. In addition, multiple different keywords were used to ensure that as many articles as possible were included in the review. Inaccuracy in document inclusion and data extraction was limited by the work of three reviewers (S. Pancani, D. Morosetti and G. Consales). Disagreements between reviewers were resolved by discussion.

The titles, abstracts and manuscripts of the documents that emerged from the search were analysed. Articles reporting the differences in D-dimer between healed/survived patients and those who reached a CEP or experienced complications such as ARDS, organ failure or multi-organ failure were included.

Results {#s3}
=======

From the initial search, 46 studies were collected. After excluding duplicates, 41 studies were identified. Among them, two case reports and two letters to authors were excluded. 20 articles with no explicit mention of D-dimer values and/or differentiation of this parameter among patient subclasses (healed/dead, severe/non-severe, *etc*.) were excluded. One article was excluded due to incongruent D-dimer measurement units. 16 articles were then reviewed: 13 between cohort and case--control studies and three cross-sectional, with a variable number of patients enrolled (7--1099). The case--control and cohort studies were demonstrated to reach the criteria for a definition of good quality (all scored ≥6); however, the cross-sectional studies did not (none scored ≥7 points). The quality assessment results are illustrated in [table 1](#TB1){ref-type="table"}.

###### 

Quality assessment with the Newcastle--Ottawa Scale \[13\]

  **First author \[ref.\]**      **Selection^\#^**   **Comparability^¶^**   **Outcome/exposure^+^**   **Total score^§^**
  ----------------------------- ------------------- ---------------------- ------------------------- --------------------
  **Cohort/case--control**                                                                           
   C[hen]{.smallcaps} \[14\]             4                    0                        3                      7
   G[uan]{.smallcaps} \[3\]              4                    0                        3                      7
   H[an]{.smallcaps} \[15\]              4                    0                        3                      7
   H[uang]{.smallcaps} \[1\]             4                    0                        3                      7
   T[ang]{.smallcaps} \[16\]             4                    0                        3                      7
   T[ang]{.smallcaps} \[17\]             4                    0                        3                      7
   W[ang]{.smallcaps} \[18\]             4                    0                        3                      7
   W[ang]{.smallcaps} \[19\]             4                    2                        3                      9
   W[u]{.smallcaps} \[6\]                4                    0                        3                      7
   Y[in]{.smallcaps} \[20\]              3                    0                        3                      6
   Z[hang]{.smallcaps} \[21\]            4                    0                        3                      7
   Z[hou]{.smallcaps} \[22\]             4                    2                        3                      9
   Z[hang]{.smallcaps} \[23\]            3                    0                        3                      6
  **Cross-sectional**                                                                                
   Z[hang]{.smallcaps} \[24\]            4                    0                        2                      6
   L[i]{.smallcaps} \[25\]               3                    0                        2                      5
   W[an]{.smallcaps} \[26\]              4                    0                        2                      6

^\#^: range 0--4 for cohort/case--control, 0--5 for cross-sectional; ^¶^: range 0--2 for all studies; ^+^: range 0--3 for all studies; ^§^: range 0--9 for cohort/case--control, 0--10 for cross-sectional.

The demographic characteristics and rates of comorbidities, ICU admission, complications and death related to the included studies are reported in [table 2](#TB2){ref-type="table"}. The main D-dimer-associated outcome and complication data of the study populations are summarised in [table 3](#TB3){ref-type="table"}.

###### 

Demographic characteristics and rates of comorbidities, intensive care unit (ICU) admission, major complications and death in the studied populations

  **First author \[ref.\]**         **Patients n**   **Mean age years**   **Male %**    **Comorbidity %**   **ICU %**   **Complications %**   **Death %**                                                              
  -------------------------------- ---------------- -------------------- ------------- ------------------- ----------- --------------------- ------------- ------------ ---------- --------- ------------------------- -----------------
  **C[hen]{.smallcaps} \[14\]**          274                 62            55/73^\#^        39/63^\#^                        1/17^\#^             17        52/100^\#^   1/25^\#^   2/9^\#^   17/77^\#,¶^; 3/49^\#,+^        14.1
  **G[uan]{.smallcaps} \[3\]**           1099                47              58.10            23.70             5              0.10               1.1          3.40        0.50                                               1.4
  **H[an]{.smallcaps} \[15\]**            94                                 51.00                                                                                                                                     
  **H[uang]{.smallcaps} \[1\]**           41                 49              73.00            32.00           31.70                                7            29          7                           12                    15
  **T[ang]{.smallcaps} \[16\]**          449                65.1             60.00            60.60                           21.6^§^                                                                                        29.80
  **T[ang]{.smallcaps} \[17\]**          183                54.1             53.50            41.00                                                                                                                          11.50
  **W[an]{.smallcaps} \[26\]**           135                 47              53.3             31.9                                                0.7          15.6        3.7                          7.4                   0.7
  **W[ang]{.smallcaps} \[18\]**          138                 56              54.30            46.40           26.00                               8.7         19.60        3.60                        7.20            
  **W[ang]{.smallcaps} \[19\]**          339                 71              49.00            60.70                                               2.4           21         8.10      28.70         21^¶^/17.4^+^             19.20
  **W[u]{.smallcaps} \[6\]**             201                 51              63.70            32.80           26.40                                           41.80                                                          21.90
  **L[i]{.smallcaps} \[25\]**           25^ƒ^                73               40               100             93                                                                                                             100
  **Y[in]{.smallcaps} \[20\]**      449/104^\#\#^       65/58^\#\#^       60/69^\#\#^    60.6/61.5^\#\#^                                                                                                                29.8/15.4^\#\#^
  **Z[hang]{.smallcaps} \[21\]**          95                 49              55.80                                                                                                                                         26.3^¶¶^
  **Z[hang]{.smallcaps} \[24\]**         140                 57              50.70            64.30           51.50                                                                                                    
  **Z[hou]{.smallcaps} \[22\]**          191                 56               62              48.00            26                                 20            31          15                      17^¶^/23^+^              28.20
  **Z[hang]{.smallcaps} \[23\]**          7                  59              57.10            42.90            100                                                                                                           71.40

DIC: disseminated intravascular coagulation; ARDS: acute respiratory distress syndrome. ^\#^: recovered/non-recovered; ^¶^: acute cardiac injury; ^+^: heart failure; ^§^: sepsis-induced coagulopathy \[27\]; ^ƒ^: deceased COVID-19; ^\#\#^: deceased COVID-19/non-COVID-19; ^¶¶^: composite end-point.

###### 

Outcome and complication differences in the studied populations based on D-dimer levels

  **First author \[ref.\]**                                   **Patients n**                     **Compared data**                            **Higher value**                                          **p-value**
  ---------------------------------------- ----------------------------------------------------- -------------------------------------------- --------------------------------------------------------- -------------
  **C[hen]{.smallcaps} \[14\]**                                     274                          D-dimer: deceased/survivors                  Deceased: 4.6 µg·mL^−1^                                   
  **G[uan]{.smallcaps} \[3\]**                                     1099                          D-dimer: CEP/non-CEP                         ≥0.5 mg·L^−1^ in 69.4% of CEP                             
  D-dimer: severe/non-severe                         ≥0.5 mg·L^−1^ in 59.6% of severe                                                                                                                   
  **H[an]{.smallcaps} \[15\]**                                      94                           D-dimer: COVID-19/non-COVID-19               COVID-19: 10.36±25.31 mg·L^−1^                            \<0.001
  D-dimer: severe/non-severe COVID-19              Severe COVID-19: 19.1±35.48 mg·L^−1^          \<0.05                                                                                                 
  **H[uang]{.smallcaps} \[1\]**                                     41                           D-dimer: ICU/non-ICU                         ICU: 2.4 mg·L^−1^, range 0.6--14.4 mg·L^−1^               0.0042
  **T[ang]{.smallcaps} \[16\]**                                     449                          D-dimer: heparin yes/no                      No heparin: \>3.0 µg·mL.                                  
  Mortality^\#^: heparin yes/no                            No heparin^\#^: 52.4%                 0.017                                                                                                  
  **T[ang]{.smallcaps} \[17\]**                                     183                          D-dimer: deceased/survivors                  Deceased: 2.12 µg·mL^−1^, range 0.77--5.27 µg·mL^−1^      \<0.001
  **W[an]{.smallcaps} \[26\]**                                      135                          D-dimer: severe/non-severe                   Severe: 0.6 mg·L^−1^, range 0.4--1.1 mg·L^−1^             \<0.001
  **W[ang]{.smallcaps} \[18\]**                                     138                          D-dimer: ICU/non-ICU                         ICU: 414 mg·L^−1^, range 191--1324 mg·L^−1^               \<0.001
  33                                                    D-dimer: deceased/survivors              Deceased: \>1000 mg·L^−1^                    \<0.05                                                    
  **W[ang]{.smallcaps} \[19\]**                                     339                          D-dimer: deceased/survivors                  Deceased: 4.38 mg·L^−1^, range 1.32--17.0 mg·L^−1^        \<0.001
  **W[u]{.smallcaps} \[6\]**                                        201                          D-dimer: ARDS/non-ARDS                       ARDS: 0.52 µg·mL^−1^ higher than non-ARDS                 \<0.001
  D-dimer: ARDS deceased/survivors          ARDS deceased: 2.10 µg·mL^−1^ higher than survivors  \<0.001                                                                                                
  **L[i]{.smallcaps} \[25\]**                                       25                           D-dimer deceased: first test/last test       Last test: 9.93 mg·L^−1^, IQR 2.65--54.8 mg·L^−1^         
  **Y[in]{.smallcaps} \[20\]**                                      553                          Mortality^\#^: COVID-19 heparin yes/no       No heparin^\#^: 52.4%                                     0.017
  Mortality: non-COVID-19 heparin yes/no                                                                                                                                                                
  **Z[hang]{.smallcaps} \[21\]**                                    95                           D-dimer: severe/non-severe                   \>1 mg·L^−1^: 81.2% severe                                \<0.001
  D-dimer: CEP/non-CEP                                    \>1 mg·L^−1^: 71.9% CEP                \<0.001                                                                                                
  **Z[hang]{.smallcaps} \[24\]**                                    140                          D-dimer: severe/non-severe                   Severe: 0.4 µg·mL^−1^, range 0.2--2.4 µg·mL^−1^           \<0.001
  **Z[hou]{.smallcaps} \[22\]**                                     172                          D-dimer: deceased/survivors                  Deceased: 5.2 µg·mL^−1^, range 1.5--21.16 µg·mL^−1^       \<0.001
  D-dimer^¶^: deceased/survivors                     \>1 µg·mL^−1^ in 81% of deceased            \<0.001                                                                                                
  **Z[hang]{.smallcaps} \[23\]**                                     7                           D-dimer: pre-limb ischaemia/limb ischaemia   \>21 µg·mL^−1^ in 71.4% of patients with limb ischaemia   

CEP: composite end-point; ICU: intensive care unit; ARDS: acute respiratory distress syndrome; IQR: interquartile range. ^\#^: D-dimer \>3.0 µg·mL^−1^; ^¶^: D-dimer \>1.0 µg·mL^−1^.

C[hen]{.smallcaps} *et al*. \[[@C14]\] (799 COVID-19 patients, among whom the characteristics were analysed of 274 healed and 13 deceased) found markedly higher D-dimer levels in the deceased group during hospitalisation than in survivors (4.6 µg·mL^−1^ *versus* 0.6 µg·mL^−1^); in addition, 35% of deceased patients *versus* 2% of survivors had D-dimer levels \>21 µg·mL^−1^.

Among the patients evaluated by G[uan]{.smallcaps} *et al*. \[[@C3]\] (1099 COVID-19 patients, 67 CEP, 15 deceased), in those who reached the CEP, D-dimer levels were ≥0.5 mg·L^−1^ in 34 out of 49 analysed cases (69.4%; *versus* 44.2% in non-CEP). Moreover, D-dimer levels were ≥0.5 mg·L^−1^ in 65 out of 109 severe cases (59.6%; *versus* 43.2% in non-severe ones).

In the work of H[an]{.smallcaps} *et al*. \[[@C15]\] (94 COVID-19 patients, 40 healthy controls), among the infected group, during hospitalisation, mean±[sd]{.smallcaps} D-dimer levels were higher than in the control group (10.36±25.31 mg·L^−1^ *versus* 0.26±0.18 mg·L^−1^; p\<0.001). D-dimer levels appeared to increase with disease severity: those with ordinary (mild) disease had 2.14±2.88 mg·L^−1^ (p\<0.001 *versus* controls), those with severe disease had 19.1±35.48 mg·L^−1^ (p\<0.01 *versus* controls), and those with critical disease had 20.04±32.39 mg·L^−1^. The difference between ordinary and severe disease was significant (p\<0.05).

H[uang]{.smallcaps} *et al*. \[[@C1]\] (41 COVID-19 patients, 13 admitted to ICU care) described significantly higher D-dimer levels in ICU compared to non-ICU patients (2.4 mg·L^−1^, range 0.6--14.4 mg·L^−1^ *versus* 0.5 mg·L^−1^, range 0.3--0.8 mg·L^−1^; p=0.0042).

T[ang]{.smallcaps} *et al*. \[[@C16]\] (449 COVID-19 patients, 94 received 40--60 mg·day^−1^ enoxaparin and five received 10 000--15 000 U·day^−1^ of unfractionated heparin) found that the 28-day mortality of heparin users was lower than that of non-users, in patients who had increased D-dimer values (\>3 µg·mL^−1^, six-fold higher than the normal upper limit). Mortality rates did not differ among heparin users according to D-dimer values; however, mortality was raised alongside the increase in D-dimer in non-users. When the D-dimer levels reached six-fold the normal upper limit, a reduction of 20% in the mortality rate was found in heparin users compared to non-users (32.8% *versus* 52.4%; p=0.017).

In the work of T[ang]{.smallcaps} *et al.* \[[@C17]\] (183 COVID-19 patients, 21 dead), at admission, mean D-dimer levels in non-survivors were significantly higher compared to survivors and the total population (2.12 µg·mL^−1^, range 0.77--5.27 µg·mL^−1^ *versus* 0.66 µg·mL^−1^, range 0.38--1.50 µg·mL^−1^ and 0.61 µg·mL^−1^, range 0.35--1.29 µg·mL^−1^, respectively; p\<0.001).

W[an]{.smallcaps} *et al*. \[[@C26]\] describe 135 COVID-19 patients: 95 (75.4%) with mild and 40 (29.6%) with severe disease. Severe cases had higher D-dimer mean values compared with mild ones (0.6 mg·L^−1^, range 0.4--1.1 mg·L^−1^ *versus* 0.3 mg·L^−1^, range 0.2--0.5 mg·L^−1^, respectively; p\<0.001).

In the study by W[ang]{.smallcaps} *et al.* \[[@C18]\] (138 COVID-19 patients, 36 admitted to ICU), D-dimer levels were higher in ICU than in non-ICU patients (414 mg·L^−1^, range 191--1324 mg·L^−1^, *versus* 166 mg·L^−1^, range 101--285 mg·L^−1^; p\<0.001). An additional evaluation on 33 patients with complete data collection was made: D-dimer levels increased until death and were higher compared to those of survivors (D-dimer levels at 13 days from admission into the ICU were \>1000 mg·L^−1^ in non-survivors *versus* \<500 mg·L^−1^ in survivors; p\<0.05).

W[ang]{.smallcaps} *et al*. \[[@C19]\] (339 elderly COVID-19 patients, mean±[sd]{.smallcaps} age 71±8 years, 80 critical, 159 severe, 100 moderate disease, 65 dead) found D-dimer levels significantly higher in the deceased compared to survivors (4.38 mg·L^−1^, range 1.32--17.0 mg·L^−1^ *versus* 1.08 mg·L^−1^, range 0.52--2.05 mg·L^−1^; p\<0.001). In univariate Cox regression for prognostic factors, D-dimer had a hazard ratio of 1.016 (95% CI 1.009--1.022) with p\<0.001.

In the article by W[u]{.smallcaps} *et al*. \[[@C6]\] (201 patients, 41.8% with ARDS, among these 52.4% deceased), D-dimer values in ARDS patients were significantly higher compared with non-ARDS patients (difference between the two groups 0.52 µg·mL^−1^, 95% CI 0.21--0.94 µg·mL^−1^; p\<0.001). In ARDS patients who died, D-dimer levels were significantly higher compared with ARDS patients who survived (difference between the two groups 2.10 µg·mL^−1^, 95% CI 0.89--5.27 µg·mL^−1^; p\<0.001). In the bivariate Cox regression analysis for risk factors, D-dimer was significantly associated with ARDS and progression from ARDS to death (hazard ratio 1.03, 95% CI 1.01--1.04; p\<0.002).

L[i]{.smallcaps} *et al*. \[[@C25]\] retrospectively reviewed data from 25 deceased COVID-19 patients, showing D-dimer level elevation at the last measurement before death in 75% of analysed patients, compared to admission values (median D-dimer level at admission 1.18 mg·L^−1^, interquartile range (IQR) 0.42--4.04 mg·L^−1^ *versus* 9.93 mg·L^−1^, IQR 2.65--54.8 mg·L^−1^ before death).

In the work of Y[in]{.smallcaps} *et al.* \[[@C20]\] (449 severe COVID-19 and 104 severe non-COVID-19 pneumonia), 99 (22%) COVID-19 patients received heparin treatment (94 received 40--60 mg·day^−1^ enoxaparin and five received 10 000--15 000 U·day^−1^ unfractionated heparin) and 22 (21.2%) non-COVID-19 patients received heparin treatment (20 received 40--60 mg·day^−1^ enoxaparin and two received 10 000--15 000 U·day^−1^ unfractionated heparin). No difference in the 28-day mortality between COVID-19 heparin users and non-users was found. When D-dimer was \>3.0 µg·mL^−1^, mortality was significantly lower in COVID-19 heparin users compared to COVID-19 non-users (32.8% *versus* 52.4%; p=0.017), while no mortality difference was detected between non-COVID-19 heparin users and non-users.

In the study of Z[hang]{.smallcaps} *et al.* \[[@C21]\] (95 COVID-19 patients with no documented comorbidity, of whom 32 severe, 63 non-severe, and 25 CEP, 70 non-CEP), patients were stratified according to D-dimer levels in two groups: ≤1 mg·L^−1^ and \>1 mg·L^−1^. In the ≤1 mg·L^−1^ group, 9.5% of cases were severe and 3.2% achieved the CEP, while in the \>1 mg·L^−1^ group, 81.2% of cases were severe and 71.9% achieved the CEP (both p\<0.001). Elevation of D-dimer level was strongly associated with severe forms of COVID-19 pneumonia and with the presence of a CEP (both p\<0.001).

Z[hang]{.smallcaps} *et al*. \[[@C24]\] (140 COVID-19 patients, 58 severe, 82 non-severe) reported significantly higher mean D-dimer values in severe compared to non-severe cases (0.4 µg·mL^−1^, range 0.2--2.4 µg·mL^−1^ *versus* 0.2 µg·mL^−1^, range 0.1--0.3 µg·mL^−1^; p\<0.001).

In the work of Z[hou]{.smallcaps} *et al.* \[[@C22]\] (191 COVID-19 patients, 137 survivors, 54 non-survivors), the mean D-dimer levels of 172 patients from the study population were significantly higher in non-survivors compared to survivors (5.2 µg·mL^−1^, range 1.5--21.16 µg·mL^−1^ *versus* 0.6 µg·mL^−1^, range 0.3--1.06 µg·mL^−1^; p\<0.0001), with values \>1 µg·mL^−1^ in 81% of non-survivors *versus* 24% of survivors, values of 0.5--1 µg·mL^−1^ in 11% of non-survivors *versus* 33% of survivors, and values \<0.5 µg·mL^−1^ in 7% of non-survivors *versus* 43% of survivors. In univariable and multivariable logistic variation analysis, D-dimer levels \>1 µg·mL^−1^ were associated with increased odds of in-hospital death (univariable analysis showed odds ratio 20.04 µg·mL^−1^, 95% CI 6.52--61.56 µg·mL^−1^, p\<0.0001; multivariable analysis showed odds ratio 18.42 µg·mL^−1^, 95% CI 2.64--128.55 µg·mL^−1^, p=0.0033).

In the work of Z[hang]{.smallcaps} *et al*. \[[@C23]\] (seven COVID-19 ICU patients, who developed critical limb ischaemia), mean D-dimer levels at ICU admission were 7.3 µg·mL^−1^ (range 1.25--21.00 µg·mL^−1^). At the time of limb ischaemia occurrence, median D-dimer increased to \>20-fold the normal range and in five patients (71.4%) it exceeded the limit of detection (\>21 µg·mL^−1^). After 3--5 days of anticoagulants, D-dimer levels decreased, but remained above the upper limit of normal (0.5 µg·mL^−1^) in all patients (lowest value 3.36 µg·mL^−1^). Among the seven patients, those meeting the DIC diagnosis criteria \[[@C27]\] passed from 0% at admission to 57.14% at the time of thrombosis, to 42.8% after anticoagulant therapy \[[@C23]\].

Discussion {#s4}
==========

Hypercoagulability, injury of the endothelium and venous stasis, defining the Virchow triad, represent the cardinal inducers of thrombus formation. Conditions predisposing to thrombosis directly or indirectly involve mechanisms associated with this triad \[[@C28]\]. The role of inflammation and hypoxia, among the pathogenetic pathways of hypercoagulative states and thrombosis, has been extensively studied \[[@C29]--[@C33]\]. It has been demonstrated that inflammatory settings, where the release of cytokines such as interleukin (IL)-1, tumour necrosis factor (TNF)-α and complement factors is consistent, induce an upregulation of plasminogen activator inhibitor (PAI)-1 with consequent impairment of fibrinolysis. Moreover, they cause pro-inflammatory changes of endothelial cells that increase the expression of chemoattractants and adhesion molecules necessary for mononucleate activation and extravascular transformation in macrophages \[[@C11], [@C30], [@C34]--[@C36]\]. Mononucleate cells are stimulated by circulating cytokines to produce tissue factor, trigger and initiator of coagulative extrinsic cascades \[[@C30], [@C37]\]. In addition, pro-inflammatory cytokines such as IL-6 and IL-8, and platelets themselves, induce platelet activation and cooperate in the propagation and maintaining of coagulative mechanisms \[[@C35], [@C38]\].

Products of coagulation eventually perpetuate inflammatory pathways through a stimulation of leukocytes, which enhances the production of cytokines such as IL-1 and IL-6, therefore indirectly perpetrating coagulative mechanisms \[[@C35], [@C39]\].

In a positive loop of reciprocal induction, hypoxia not only is a consequence of vascular occlusion, but can also stimulate thrombus formation and propagation, through the activation of multiple cellular and molecular pathways. These include hypoxia-inducible factors (HIFs), more precisely HIF1 and HIF2 \[[@C30], [@C40], [@C41]\]. In hypo-oxygenation, nuclear dimerisation of HIFs is extremely enhanced, with consequent activation of hypoxia responsive element and transcription of genes coding for molecules directly implicated in coagulative homeostasis such as PAI-1 \[[@C28], [@C42]\]. Hypoxia also induces the production of molecules such as early growth response-1, TNF-α, IL-1 and other regulators of thrombus formation and reduces that of thrombomodulin, therefore inducing pro-thrombotic changes and progressively reducing the fibrinolytic activity of the endothelium \[[@C28], [@C43], [@C44]\].

During sepsis, multiple factors enhancing coagulation are activated. The pathogen-related cellular damage and immune responses stimulate the production of molecules such as the pathogen-associated molecular patterns (PAMPs). PAMPs induce the release from damaged cells of DNA, histones and pattern-recognising receptors, promoters of both inflammation and coagulation \[[@C45], [@C46]\]. Other mediators implicated are represented by neutrophil extracellular traps (NETs). When activated by pathogens such as viruses or stimulated by molecules such as endothelial P-selectin, neutrophils can induce NETosis, a specific kind of apoptosis. NETosis results in the production of extracellular proteins, histones and DNA-intertwined compounds implicated in hypercoagulative states by acting as a scaffold for thrombus formation \[[@C46]\].

Pathogenetic mechanisms of SARS-CoV-2 infections involve the binding of virus envelope glycoprotein to ACE2 \[[@C10], [@C11]\]. ACE2 can be identified on the cells of multiple tissues, particularly alveolar epithelial, endothelial, intestinal epithelial and others \[[@C23]\]. The innate tropism for vascular endothelial cells and their consequent damage, together with the intense activation of inflammatory responses and of coagulation pathways, may explain the intense pro-coagulative state \[[@C47]\]. This predisposes to systemic micro-thrombotic alterations and may give a partial explanation to the consistent rate of multi-organ failure, DIC and, based on the consistent involvement of lung structures, of ARDS in severe COVID-19 patients.

D-dimer is an indirect marker of active coagulation and thrombin formation. It is in fact released when plasmin, a fibrinolytic enzyme, cleaves fibrin to degrade clots and represents a mirror of the endovascular thrombotic processes \[[@C48]\].

The alterations of coagulation factors during SARS-CoV-2 infection and specifically that of D-dimer are, as documented in the clinical experiences described here, severe, constant and correlated with prognosis, complications and CEP rates. As reported by T[ang]{.smallcaps} *et al.* \[[@C17]\], mean D-dimer levels in non-survivors were significantly higher compared to survivors and, based on the experience of W[ang]{.smallcaps} *et al.* \[[@C18]\], those levels continue to increase until death with higher values compared to survivors. Additionally, D-dimer appears significantly higher in severe patients compared to non-severe ones, as shown in the study by Z[hang]{.smallcaps} *et al.* \[[@C24]\]. Similar results were obtained by H[uang]{.smallcaps} *et al*. \[[@C1]\], where they classified patients based on whether they were admitted to the ICU.

Among the factors that were demonstrated to be connected to the clinical outcome of COVID-19 patients, the presence of comorbidities may represent a confounding factor for the interpretation of D-dimer and other coagulation parameter alterations, especially considering the heterogeneous aetiology of thrombotic and thrombophilic states. However, as emerged from the article by Z[hang]{.smallcaps} *et al.* \[[@C21]\], elevations of D-dimer levels were strongly associated with severe forms of COVID-19 and with the presence of a CEP (both p\<0.001). Also, in the work of H[an]{.smallcaps} *et al.* \[[@C15]\], mean D-dimer levels in COVID-19 patients were significantly higher than those in the healthy control group (p\<0.001) and increased substantially with the severity of the disease.

This hypercoagulative infection-induced state is, as previously mentioned, systemic, and may lead to various clinical manifestations such as limb ischaemia (as documented by Z[hang]{.smallcaps} *et al.* \[[@C23]\]), DIC and, progressively, to coagulation factor deterioration \[[@C49]\]. However, due to the more consistent tropism of this virus for lung structures, micro- and macro-thrombotic events in this organ should be primarily considered. These conditions represent severe therapeutic challenges and may require non-pharmacological, invasive rescue treatments, such as endovascular interventional ones. These represent an extra vigorous stress on already very fragile patients.

In the experience of W[u]{.smallcaps} *et al.* \[[@C6]\], D-dimer levels in COVID-19 patients with ARDS were significantly higher compared to those without ARDS, and those of deceased ARDS patients were significantly higher than those of ARDS patients who survived, with significant association between D-dimer elevation and the development of ARDS and progression from ARDS to death. In cases with sudden or progressive oxygen level deterioration, ARDS-compatible symptoms, signs of right ventricle progressive overload or diffuse perfusion alterations of micro-thrombotic aetiology, the possibility of pulmonary thromboembolism should be considered \[[@C50]\]. Enforcing this theory, recent pathology studies of deceased COVID-19 patients showed the presence of pulmonary small vessel micro-thrombotic alterations \[[@C51], [@C52]\]. Although a cost--benefit evaluation of the appropriateness of each medical action should always be performed to reduce infection transmission risk (pulmonary ventilation/perfusion examinations are, for this reason, not recommended), in cases of D-dimer progressive elevation, decay of respiratory gas exchange, as well as progressive signs of right side congestive heart failure, the hypothesis of a diagnostic investigation with pulmonary angio-CT scan should be considered, in order to promptly detect possible pulmonary embolic states and to perform adequate pharmacological interventions \[[@C53]--[@C55]\].

Similarly, in cases of parenchymal function deterioration, limb ischaemic manifestations or matching of DIC or sepsis-induced coagulopathy criteria \[[@C27]\], parenchymal and peripheral vascular Doppler-ultrasound evaluation would be useful, allowing the identification and treatment of eligible patients \[[@C56]\].

The association between SARS-CoV-2 infection and coagulation changes is becoming more defined and experience with anticoagulants, especially low-molecular-weight heparin (LMWH), as COVID-19 management drugs is progressively increasing \[[@C54], [@C55]\]. As reported in the study by T[ang]{.smallcaps} *et al.* \[[@C16]\], the 28-day mortality of patients with markedly high D-dimer levels treated with therapeutic doses of heparin was lower than that of non-treated patients, with mortality rates that were raised in non-users together with the increase of D-dimer. Similarly, Y[in]{.smallcaps} *et al*. \[[@C20]\] described no difference in the 28-days mortality between COVID-19 heparin users and non-users overall. However, when D-dimer was \>3.0 µg·mL^−1^, mortality was significantly lower in COVID-19 heparin users compared to COVID-19 non-users (p=0.017), while no mortality difference was detected between non-COVID-19 heparin users and non-users.

Anticoagulant therapy therefore represents a valid tool to use in the rehabilitation of the very fragile global homeostasis of the COVID-19 population and has proved its benefits when administered considering patients' clinical characteristics and contraindications \[[@C16], [@C20], [@C57], [@C58]\]. However, the appropriate time to start therapeutic administration of these drugs, especially aiming to intervene before patients become symptomatic due to major thrombosis-related dysfunction, has not yet been defined.

The hypothesis of an early and continuous pro-thrombotic activity of SARS-CoV-2 and therefore the appropriateness of an immediate and continuous monitoring of coagulation indicators, such as D-dimer, with consequent labelled administration of adjusted doses of anticoagulants, should be addressed further, in order to prevent worsening of global conditions due to vascular parenchymal or systemic thrombotic dysfunction.

As indicated by H[unt]{.smallcaps} *et al*. \[[@C54]\] and Z[hou]{.smallcaps} *et al*. \[[@C55]\], prophylactic anticoagulant treatment with LMWH is to be considered, always after making a precise risk stratification (*i.e.* tracheostomy access management) and an evaluation of possible contraindications (recent or forthcoming surgery, active bleedings, *etc*.). However, the precise investigation of the correct balance between D-dimer elevation, coagulation asset and doses of anticoagulants, especially in pre-symptomatic conditions, during COVID-19 disease, has not yet been performed and would be of great interest, in order to personalise treatments, to allow a graduated and targeted adjustment of doses, therefore preventing disease-related thrombotic complications and drug-induced severe coagulation disorders.

To conclude, after evaluating clinical data reported in the literature, SARS-CoV-2-induced coagulation alterations and consequent micro- and macro-thrombotic events appeared to be an issue of primary importance. This is particularly supported by the evidence of severe elevation of D-dimer levels observed in critically ill COVID-19 patients. Treatment schemes with anticoagulant drugs, especially heparin and LMWH, based on monitoring the levels of D-dimer and other coagulation factors, should be further addressed in order to define adequate timing (therapeutic and prophylactic) and efficacy, based on patients' characteristics, clinical presentations and coagulative function.

Limitations to this work were represented by the actuality of the investigated issue: available data sources are recent and therefore the knowledge on the disease\'s implication is not global. Additionally, both the studies designed specifically to investigate the implications of coagulation and D-dimer in COVID-19 disease and those reporting explicit D-dimer-related data vary widely in terms of measurement protocols and of the investigated D-dimer-related outcomes. Despite the presence of these limitations, which are substantially related to the recent presentation of COVID-19, the examination and re-elaboration of data from clinical observations seems fundamental, in order to highlight infection-related major issues and to consequently produce evidence-based management and therapeutic solutions.
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